Position in BHC
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$228,342
+$97,182 QoQ
Shares Held
46,317
+145.4% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#116
of 220 holders
Holding Since
Mar 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BHC Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $11,914,926 across 21 Drug Manufacturers - Specialty & Generic names. BHC ranks #15 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
55,201 | $2,264,897 | |
| 2 | ZTS |
Zoetis Inc.
|
18,470 | $1,327,254 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
259,512 | $1,092,545 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
90,210 | $902,100 | |
| 5 | LQDA |
Liquidia Corp
|
10,098 | $805,113 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,219 | $717,455 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
39,241 | $704,768 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
82,830 | $656,013 |
All Filings in BHC
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $228,342 | 46,317 | Shares | Sole | 2026-08-06 | |
| 2025-12-31 | $131,160 | 18,872 | Shares | Sole | 2026-02-06 | |
| 2025-03-31 | $167,333 | 25,863 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $827,568 | 102,676 | Shares | Sole | 2025-02-07 | |
| 2024-06-30 | $390,668 | 56,050 | Shares | Sole | 2024-08-15 | |
| 2022-03-31 | $1,053,042 | 46,085 | Shares | Sole | 2022-05-11 | |
| 2021-09-30 | $256,971 | 9,227 | Shares | Sole | 2021-11-12 | |
| 2020-03-31 | $691,145 | 44,590 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||